KR100632725B1 - 오메프라졸의 제조 방법 - Google Patents

오메프라졸의 제조 방법 Download PDF

Info

Publication number
KR100632725B1
KR100632725B1 KR1020017001737A KR20017001737A KR100632725B1 KR 100632725 B1 KR100632725 B1 KR 100632725B1 KR 1020017001737 A KR1020017001737 A KR 1020017001737A KR 20017001737 A KR20017001737 A KR 20017001737A KR 100632725 B1 KR100632725 B1 KR 100632725B1
Authority
KR
South Korea
Prior art keywords
delete delete
methanol
aqueous
omeprazole
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020017001737A
Other languages
English (en)
Korean (ko)
Other versions
KR20010072382A (ko
Inventor
아누시스닉
뱅크스벤자민뉴튼
맥마누스제임스더블유
초우링웬
리우후이
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22254872&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100632725(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20010072382A publication Critical patent/KR20010072382A/ko
Application granted granted Critical
Publication of KR100632725B1 publication Critical patent/KR100632725B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020017001737A 1998-08-11 1999-08-06 오메프라졸의 제조 방법 Expired - Fee Related KR100632725B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9603798P 1998-08-11 1998-08-11
US60/096,037 1998-08-11

Publications (2)

Publication Number Publication Date
KR20010072382A KR20010072382A (ko) 2001-07-31
KR100632725B1 true KR100632725B1 (ko) 2006-10-16

Family

ID=22254872

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017001737A Expired - Fee Related KR100632725B1 (ko) 1998-08-11 1999-08-06 오메프라졸의 제조 방법

Country Status (18)

Country Link
US (2) US6166213A (https=)
EP (1) EP1104417B1 (https=)
JP (1) JP2002522537A (https=)
KR (1) KR100632725B1 (https=)
CN (1) CN1227246C (https=)
AT (1) ATE360626T1 (https=)
AU (1) AU764642B2 (https=)
BR (1) BR9912883A (https=)
CA (1) CA2338967A1 (https=)
DE (1) DE69935915T2 (https=)
DK (1) DK1104417T3 (https=)
ES (1) ES2285857T3 (https=)
IL (2) IL141324A0 (https=)
NO (1) NO321054B1 (https=)
NZ (1) NZ509798A (https=)
PT (1) PT1104417E (https=)
WO (1) WO2000009497A1 (https=)
ZA (1) ZA200101140B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023048508A1 (ko) * 2021-09-23 2023-03-30 국립암센터 오메프라졸 갈변물질을 포함하는 암 예방 또는 치료용 약학적 조성물

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6303787B1 (en) * 1998-05-27 2001-10-16 Natco Pharma Limited Intermediates and an improved process for the preparation of Omeprazole employing the said intermediates
IL142703A (en) * 1998-11-10 2006-04-10 Astrazeneca Ab Crystalline form of omeprazole
UA72748C2 (en) 1998-11-10 2005-04-15 Astrazeneca Ab A novel crystalline form of omeprazole
ES2168043B1 (es) 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
SI20875A (sl) * 2001-04-25 2002-10-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristalna oblika omeprazola
DE10140492A1 (de) 2001-08-17 2003-08-14 Gruenenthal Gmbh Hydrate von gegebenenfalls substituierten 2-(2-Pyridinyl)methylthio-1H-benzimidazolen und Verfahren zu ihrer Herstellung
WO2003063840A2 (en) * 2002-01-25 2003-08-07 Santarus, Inc. Transmucosal delivery of proton pump inhibitors
KR100873419B1 (ko) * 2002-06-18 2008-12-11 페어차일드코리아반도체 주식회사 높은 항복 전압, 낮은 온 저항 및 작은 스위칭 손실을갖는 전력용 반도체 소자
EP1764364A1 (en) * 2002-08-21 2007-03-21 Teva Pharmaceutical Industries Ltd A method for the purification of lansoprazole
US6909004B2 (en) * 2002-08-21 2005-06-21 Teva Pharmaceutical Industries Ltd. Method for the purification of lansoprazole
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
PL1802584T3 (pl) * 2004-10-11 2010-03-31 Ranbaxy Laboratories Ltd Sposób wytwarzania podstawionych sulfotlenków
US20060210637A1 (en) * 2005-03-17 2006-09-21 Qpharma, Llc Stable tablet dosage forms of proton pump inhibitors
US20070026071A1 (en) * 2005-07-28 2007-02-01 Qpharma, Llc Magnesium salt proton pump inhibitor dosage forms
EP1934201A1 (en) * 2005-10-06 2008-06-25 Auspex Pharmaceuticals Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
WO2007066202A1 (en) * 2005-12-06 2007-06-14 Inogent Laboratories Private Limited Process for the preparation of 2-(2-pyridylmethyl)-sulfinyl-1h-benzimidazoles
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
US7579476B2 (en) * 2006-02-24 2009-08-25 Praktikatalyst Pharma, Llc Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals
EP2068841B1 (en) 2006-10-05 2018-09-26 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
CA2667682A1 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
WO2009137648A1 (en) * 2008-05-09 2009-11-12 Aptapharma, Inc. Multilayer proton pump inhibitor tablets
WO2010134099A1 (en) 2009-05-21 2010-11-25 Cadila Healthcare Limited One pot process for preparing omeprazole and related compounds
CN103204841B (zh) * 2013-05-09 2014-06-25 成都天台山制药有限公司 奥美拉唑钠及制备方法
CN104592201A (zh) * 2015-01-13 2015-05-06 江苏中邦制药有限公司 一种奥美拉唑的精制方法
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
CN111635393A (zh) * 2020-06-28 2020-09-08 江苏吴中医药集团有限公司 一种艾司奥美拉唑钠的制备方法
CN112679475B (zh) * 2021-01-14 2022-02-15 四川新迪医药化工有限公司 一种奥美拉唑的制备方法及奥美拉唑
CN114209697A (zh) * 2021-12-14 2022-03-22 重庆大学附属三峡医院 一种质子泵抑制剂、制备方法及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0533264A1 (en) * 1991-09-20 1993-03-24 Merck & Co. Inc. Process for the preparation of anti-ulcer agents

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE416649B (sv) * 1974-05-16 1981-01-26 Haessle Ab Forfarande for framstellning av foreningar som paverkar magsyrasekretionen
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
JPH0643426B2 (ja) * 1986-07-25 1994-06-08 東京田辺製薬株式会社 イミダゾ〔４，５−ｂ〕ピリジン誘導体、その製造法及びそれを含有する抗潰瘍剤
DK171989B1 (da) * 1987-08-04 1997-09-08 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler
GB2239453A (en) * 1989-11-27 1991-07-03 Haessle Ab Omeprazole
SE9002043D0 (sv) * 1990-06-07 1990-06-07 Astra Ab Improved method for synthesis
ES2026761A6 (es) * 1990-10-31 1992-05-01 Genesis Para La Investigacion Procedimiento de obtencion del omeprazol.
TW359614B (en) * 1993-08-31 1999-06-01 Takeda Chemical Industries Ltd Composition containing benzimidazole compounds for rectal administration
AU5780696A (en) * 1995-06-02 1996-12-18 Takeda Chemical Industries Ltd. Stabilized composition comprising an antiulcerative benzimid azole
SE521100C2 (sv) * 1995-12-15 2003-09-30 Astra Ab Förfarande för framställning av en bensimidazolförening
SK283805B6 (sk) * 1996-09-09 2004-02-03 Slovakofarma, A. S. Spôsob prípravy omeprazolu
WO1998040378A1 (en) * 1997-03-07 1998-09-17 A/S Gea Farmaceutisk Fabrik Process for the preparation of 2-[[(2-pyridinyl)methyl]sulfinyl]-1h-benzimidazoles and novel compounds of use for such purpose
WO1998040377A1 (en) * 1997-03-07 1998-09-17 A/S Gea Farmaceutisk Fabrik Process for the preparation of 2-[[(2-pyridinyl)methyl]sulfinyl]-1h-benzimidazoles and novel compounds of use for such purpose

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0533264A1 (en) * 1991-09-20 1993-03-24 Merck & Co. Inc. Process for the preparation of anti-ulcer agents

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023048508A1 (ko) * 2021-09-23 2023-03-30 국립암센터 오메프라졸 갈변물질을 포함하는 암 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
IL141324A0 (en) 2002-03-10
EP1104417B1 (en) 2007-04-25
PT1104417E (pt) 2007-06-29
WO2000009497A1 (en) 2000-02-24
CN1227246C (zh) 2005-11-16
CA2338967A1 (en) 2000-02-24
DK1104417T3 (da) 2007-07-16
DE69935915T2 (de) 2008-01-10
CN1322201A (zh) 2001-11-14
EP1104417A1 (en) 2001-06-06
NO20010677D0 (no) 2001-02-09
ATE360626T1 (de) 2007-05-15
KR20010072382A (ko) 2001-07-31
EP1104417A4 (en) 2002-12-18
DE69935915D1 (de) 2007-06-06
BR9912883A (pt) 2001-09-25
US6147103A (en) 2000-11-14
IL141324A (en) 2007-05-15
AU764642B2 (en) 2003-08-28
US6166213A (en) 2000-12-26
NZ509798A (en) 2003-06-30
JP2002522537A (ja) 2002-07-23
NO20010677L (no) 2001-04-09
NO321054B1 (no) 2006-03-06
ES2285857T3 (es) 2007-11-16
ZA200101140B (en) 2002-04-09
AU5470999A (en) 2000-03-06

Similar Documents

Publication Publication Date Title
KR100632725B1 (ko) 오메프라졸의 제조 방법
EP1409478B1 (en) Improved process for preparing benzimidazole-type compounds
US6191148B1 (en) Omerazole process and compositions thereof
EP1681056A1 (en) Process for preparing lansoprazole
EP2030973A1 (en) Process for preparing 2-sulfinyl-1H-benzimidazoles
JP2010083897A (ja) ランソプラゾールの精製方法
WO2008001392A2 (en) An improved process for the preparation of pantoprazole and its pharmaceutically acceptable salts
EP1476441B1 (en) A method of eliminating sulfone analog in the synthesis of pyridine-benzimidazole sulfoxides
HK1034510A1 (en) Improved omeprazole process and compositions thereof
HK1034510B (en) Improved omeprazole process and compositions thereof
MXPA01001542A (en) Improved omeprazole process and compositions thereof
EP1764364A1 (en) A method for the purification of lansoprazole

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20090930

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20090930

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000